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ABSTRACT 
We have evaluated the biological efficacy of El-deleted adenoviruses in baboons for lung-directed gene therapy 
of cystic fibrosis (CF). T h e experimental design attempted to simulate a phase I clinical trial with animals 
receiving a single dose of virus to an isolated pulmonary segment. A total of 14 animals divided into four 
groups, each of which received escalating doses of virus, were used. Individual animals were necropsied 4 and 
21 days after gene transfer and tissues were carefully surveyed for gene expression. Expression ofthe transgene 
was localized primarily to the area into which it was infused; the efficiency ofrecombinant gene expression and 
the abundance of transgene sequences were proportional to dose and both diminished with time. Transgene 
expression w a s found predominantly in alveolar cells with patches of expression in the proximal and distal 
airway. Analysis of adenoviral protein expression within transgene-expressing cells revealed infrequent ex-
pression ofthe E 2 a gene and no detectable expression of late genes (i.e., fiber protein). These results suggest 
that recombinant adenovirus can be used to transfer genes efficiently to the lung of n o n h u m a n primates and 
that therapeutic strategies of cystic fibrosis m a y require repetitive administration with current vectors. 
OVERVIEW SUMMARY 
Recombinant adenoviruses hold tremendous promise for 
gene therapies of lung disease in cystic fibrosis (CF). A n 
evaluation of the feasibility and safety of this technology in 
nonhuman primates is critical in the design of clinical pro-
tocols. In a series of two papers, Wilson and colleagues 
describe an extensive study in baboons designed to evaluate 
the feasibility and safety of direct instillation of C F trans-
membrane conductance regulator (CFTR)-expressing ade-
noviruses into the airway. This paper by Engelhardt et al., 
addresses the biological efficacy of El-deleted adenoviruses 
for gene therapy of C F lung disease. 
INTRODUCTION 
ADVANCES IN GENE TRANSFER TECHNOLOGY together with an 
enhanced knowledge of the pathophysiology of cystic fi-
brosis (CF) have paved the way for the development of gene 
therapies for this lethal inherited disorder (Collins, 1992). The 
first step in the development of these therapies was the isolation 
of the gene defective in C F that encodes the C F transmembrane 
conductance regulator (CFTR) (Kerem et al., 1989; Riordan 
etal., 1989; Rommens (?t a/., 1989). Viral-mediated transduc-
tion of the normal version of this gene into isolated cells from 
patients with C F was sufficient to conect the primary cellular 
defect in CF, abnormal cAMP-mediated regulation of chloride 
conductance (Drumm £•/a/., 1990; Gregory e?a/.,, 1990). Local-
ization of CFTR in the human lung has identified a variety of cells 
throughout the proximal (Engelhardt et al., 1992) and distal lung 
(Engelhardt et al., in press) that express this gene and, therefore, 
are potential targets for CFTR gene transfer. 
A variety of viral and nonviral approaches have been evaluated 
for lung-directed gene therapy of C F (Collins, 1992). The most 
promising technology is based on recombinant adenoviruses that 
are rendered defective in replication by virtue of deletions in the 
Ela and Elb genes (Rosenfeld et al., 1991a, 1992; Engelhardt 
et al., 1993). Adenoviruses can be isolated in large quantities at 
concentrations in excess of 10'^ particles/ml, and are capable of 
transducing genes into nondividing cells (Kozarsky and Wilson, 
'Insdtute for Human Gene Therapy, University of Pennsylvania Medical Center, Wistar Institute, Philadelphia, PA 19104. 
•̂ Department of Intemal Medicine, University of Michigan, Ann Arbor, MI 48109. 
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1993). In addition, many serotypes of human adenoviruses are 
naturally tropic to the airway epithelium (Chanock, 1974). 
The potential usefulness of recombinant adenoviruses for the 
treatment of C F was initially studied in the cotton rat (Rosenfeld 
et al., 1991a,b, 1992). Direct instillation of /acZ-expressing 
adenoviruses into the airway of these animals led to high-level 
recombinant gene expression in the majority of surface epithe-
lial cells of the conducting airway (Rosenfeld et al., 1991b). 
Similar results were obtained when adenovirus expressing hu-
man C F T R was infused into the lungs of cotton rats; a low level 
of human C F T R expression was detected for up to 3 weeks 
(Rosenfeld et al.. 1992). Similar studies have been performed 
using a model of human lung that is based on the growth of a 
human bronchial xenograft in athymic mice (Engelhardt et al., 
1993). Instillafion of CFTR-expressing adenovirus into the lu-
men of C F and non-CF xenografts was associated with high 
levels of recombinant-derived C F T R protein that: (i) was local-
ized primarily to the apical plasma membrane in up to 3 0 % of 
the cells, (ii) was found in all cell types except basal cells and, 
(iii) was stable for the lifetime ofthe grafts, which was 8 weeks. 
Additional analyses of the adenovirus-infected xenografts indi-
cated that a significant number of transduced cells expressed at 
least one adenoviral early gene and that recombinant virus 
could be recovered from the lumen of the xenografts for up to 
28 days. 
W e describe in this report an evaluation in nonhuman pri-
mates of the safety and biological efficacy of recombinant ade-
noviruses for lung-directed gene therapy. The study was con-
structed to simulate a possible phase I clinical trial. Several 
issues were addressed in this preclinical study, which involved 
a dose escalation of recombinant C F T R and lacZ adenoviruses 
into segments of the lung: (i) characterization of the inflamma-
tory response in the lung, (ii) clinical evaluation of lung func-
tion, (iii) dissemination of virus into bodily fluids, (iv) effi-
ciency of gene transfer, (v) stability of transgene expression, (vi) 
evaluation of cellular targets, and (vii) expression of vu-al genes 
from recombinant adenoviral vectors. This manuscript describes 
analyses that address biological efficacy while the companion 
manuscript describes clinical and padiological consequences of 
adenovirus-mediated gene transfer (Simon etal., 1993). 
METHODS 
Preparation of recombinant adenovirus 
The recombinant CFTR adenovirus (Ad.CBCFTR) contains 
the cytomegalovirus (CMV) enhancer, (J-actin promoter, hu-
man CFTR cDNA, and SV40 poly(A) minigene cassette in-
serted into the El-deleted region (spanning 1.0-9.2 map units) 
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FIG. 1. Anatomical localization of tacZ transgene activity by in situ X-gal staining. Lungs from Bl infected with 10'° pfu/ml 
were harvested 3 days post-infection and histochemically stained for P-gal with X-gal by intrabronchial instillafion. A. Left lung 
following 30 min staining in X-Gal. B. Wedge ofthe upper left lobe in which X-gal staining demarcates the posterior segment. 
Closed anow designates area of infusion of virus in the posterior segment of the left upper lobe. Open anow designates area of 
spillover of virus to the left lower lobe. 
FIG. 2. Effect of viral dose on lacZ transgene expression. Tissue from the posterior segment of the left upper lobe of lungs 
infected with 10'° pfu/ml (A, demonstrating alveolar staining; B, demonstrating staining in a major bronchus), 10'' pfu/ml (C), and 
10** pfu/ml (D), at 4 days postinfection with Ad.CMV/acZ and histochemically stained in X-gal for 30 min. Absence of staining in 
the same region of the left upper lobe of an animal infected with 10'° pfu/ml at 21 days (E). 
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of modified adenovirus type 5 (AdS). The remaining sequences 
are derived from ̂ //700l, in which the majority of the E3 region 
(map units 78.4-86) was deleted (Engelhardt etal., 1993; Yang 
et al., 1993). Recombinant lacZ adenovirus (Ad.CMV/acZ) 
contains the C M V promoter, cytoplasmic /c;cZ gene, and SV40 
poly(A) minigene cassette inserted into the El-deleted (span-
ning 1.0-9.2 map units) region of AdS strain sub360, in which 
78.4-8S map units of E3 has been deleted (Engelhardt et al., 
1993; Yang et al., 1993). Viral stocks were generated from 
confluent monolayers of 293 cells infected with purified recom-
binant adenoviral stocks at amultiplicity of infection (m.o.i.) of 
10. Cells were harvested 36-40 hr post-infection, pelleted, 
resuspended in 10 m M Tris-Cl pH 8.1, and lysed by three 
cycles of freeze-thawing. Cell debris was removed by centrifu-
gation and supernatants were subjected to two rounds of CsCI 
gradient purification. Concentrated virus was desalted by gel 
filtration in phosphate-buffered saline (PBS) containing 1 0 % 
glycerol for cryopreservation at — 80°C. Concentrated stocks 
were diluted to a final concentration of 2 % PBS, 0.2% glycerol, 
in isotonic saline for all viral instillations just prior to use. 
General study design 
Fourteen male baboons ranging in weights from 7 to 33 kg 
were used in this study; 7 were caught in the wild and the 
remaining 7 were bred in captivity. Descripfions of animals and 
the recombinant viruses used are provided in Table 1. Careful 
observation and physical examination indicated that all animals 
were clinically within normal limits. Several animals demon-
strated mildly abnormal laboratory values or abnormal findings 
at necropsy (summarized in Simon et al., 1993). One larger 
animal, B1, was used to evaluate the anatomical localization of 
lacZ transgene activity following instillation of 20 ml (I0'° 
pfu/ml) of Ad.CMV/acZ into the posterior segment of the left 
upper lobe via a balloon catheter placed through a broncho-
scope that was held in place for 10 min. Following instillation, 
the bronchoscope was removed with no attempt to aspirate 
remaining virus. O n day 3 post-instillation of virus, the animal 
was necropsied and the whole lung was removed for in situ 
X-gal detection of p-galactosidase (P-gal) activity. The second 
large animal (B2) had 20 ml of 10'° pl'u/ml Ad.CMV/acZ and 
Ad.CBCFTR placed into the posterior segments of the left and 
right upper lobes, respectively, by the same technique. The 
remaining 12 baboons were used in a dose-escalafion study that 
evaluated the efficiency of C F T R and lacZ gene transfer at 
doses ranging from 10' to 10'" pfu/ml. The animals in the 
dose-escalation study were approximately three-fold smaller 
than those used in Studies I and II, therefore the volume of 
instilled virus was decreased from 20 ml to 7 ml. In these 
smaller animals, a pediatric bronchoscope was wedged into the 
posterior segments of the right upper lobe and left upper lobe to 
infuse Ad.CBCF77? and AdCMVIacZ. respectively. The bron-
choscope was held in place for 10 min, after which it was 
removed without aspiration of remaining virus. The viral doses 
of the four treatment groups were as follows (see also Table I): 
Group A — B 4 , B6, B8, 10'° pfu/ml, 7.3 X 10'' pfu/kg (ave); 
G r o u p B — B I I , B3, BIS, 10" pl'u/ml, 9.7 x 10** pfu/kg (ave); 
Group C — B I O , BI4, BI6, 10" pfu/ml, 9 x 10' pfu/kg (ave); 
and Group D — B 3 , BS, B7, 10' pfu/ml, 7 x 10'' pfu/kg (ave). 
For each viral dose, one animal was necropsied at 4 days and 
another at 21 days. The remaining animals are cunentiy being 
evaluated in long-term studies that include repeat bronchoscopy 
4 days and 21 days after virus instillation to recover bronchoal-
veolar lavage and surface epithelial cells (see Simon et al., 
1993). 
Necropsy protocol 
Following euthanasia by an intravenous injection with 
pentobarbital/phenytoin, the lungs were analyzed for gross pa-
thology and the heart lung cassette was removed en bloc from 
approximately the I Oth most proximal tracheal cartilaginous 
ring. The lungs were immediately placed on ice and dissected 
into quadrants for analysis of transgene expression and histopa-
thology. With the exception of animal Bl, in which the seg-
mental bronchus to the left lung was canulated for in situ detec-
tion of p-gal, the dissection of lungs from all other baboons was 
performed in the following manner. The upper lobes were di-
vided into four quadrants designated L U L I , L U L 2 , L U L 3 , 
L U L 4 for left upper lobe, and R U L I , R U L 2 , R U L 3 , R U L 4 for 
right upper lobe. Typically the first two quadrants harvested 
from each lobe L U L I , L U L 2 , L U R l , and L U R 2 were within 
the anatomical region predicted to have been instilled with 
virus. The left middle (LML), right middle ( R M L ) , left lower 
(LLL), and right lower (RLL) lobes were divided into two 
sections for analysis of transgene expression and histopathol-
ogy. These samples were designated L M L l , L M L 2 , R M L I , 
R M L 2 . LLLI. LLL2, RLLl, and RLL2. All tissue quadrants 
were further divided into four parts: (i) fresh frozen in O C T for 
in situ hybridization and immunocytochemistry, (ii) fixed in 
formalin for histopathology, (iii) snap-frozen in liquid nitrogen 
for nucleic acid analysis, or (iv) fixed in glutaraldehyde for 
histochemical detection of P-gal activity, en bloc. All lobes of 
the lung were processed in this manner except for the azygos, 
which was too small to divide into quadrants and was retained 
solely for histopathology. 
T w o quadrants were also harvested from other organs, in-
cluding the heart, liver, spleen, kidney, urinary bladder, brain, 
testes, and lymph nodes. These quadrants were divided into 
four subquadrants and processed for the analyses described 
above. 
Histochemical and immunohistochemical analysis of 
lungs for ^-gal, C F T R , and adenoviral proteins 
To investigate the anatomical distribution of lacZ expression 
following bronchoscopic instillation into the posterior segment 
of the left upper lobe, the left lung from one animal (Bl) 
infected with Ad.CMV/acZ was histochemically stained by in-
tratracheal instillation of X-gal. Briefly, the left mainstem bron-
chus was canulated and distended with PBS containing 0.5% 
glutaraldehyde for 2 hr. Following fixation, the lung was lav-
aged four times with PBS containing I m M M g C L for 15 min 
each. The lung was then distended with X-gal solution and 
stained al 37°C for 30 min (Price etal., 1986). After histochem-
ical staining, the lungs were lavaged with four changes of PBS 
followed by instillation of buffered formalin. Lungs from the 
remaining animals were similarly evaluated for lacZ expres-
sion, except that specific subquadrants of the dissected lobes 
were stained en bloc. Brushings from long-term animals were 
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evaluated on day 4 and 21 for lacZ activity on cytospun slides 
stained in X-gal for 4 hr. 
C F T R protein expression was evaluated by indirect immuno-
fluorescence using a purified polyclonal antibody generated 
against the carboxy terminus ofhuman C F T R (a-1468 C F T R [a 
generous gift from Jonathan Cohn, Duke University)) as previ-
ously described (Marino et al., 1991; Engelhardt et al.. 1992, 
1993, and in press; Yang et al.. 1993a.b). Frozen sections (6 
p,m) or cytospun bronchial brushings were post-fixed in metha-
nol for 10 min at -20°C followed by air drying. After blocking 
in PBS containing 20%- donkey serum (DS), sections were 
incubated for 90 min in l.5%- DS/PBS containing 5 p,g/ml 
a-1468 C F T R followed by washing in three changes of I.S% 
DS/PBS for 8 min each. Sections were incubated in 1.5% 
DS/PBS containing 5 p,g/ml donkey anti-rabbit FITC-conju-
gated antibody for 30 min. Finally, sections were washed, 
mounted in antifadent (Citifluor), and analyzed by fluorescent 
microscopy. 
Studies evaluating the expression of adenoviral proteins from 
recombinant vectors were performed as previously described by 
immunocytochemical colocalization of P-gal, adenoviral fiber 
protein, and adenoviral D B P protein (Engelhardt et al., 1993). 
Sections were incubated sequentially with 66 p,g/ml rabbit anti-
P-gal (S'-»-3' Inc), a I/IO dilution of hybridoma supematant to 
AdS D B P , 5 p.g/ml of both donkey anti-rabbit-AMCA and 
donkey anti-mouse-texas red. followed by a 1/10 dilution of 
mouse anti-Ad3 fiber-FITC (Ab50l6, Chemicon Inc). 
In situ detection of CFTR mRNA 
In situ hybridization was performed as previously described 
using 6-p.m frozen sections (Engelhardt et al., 1992). A viral-
specific probe (116 bp) to the 3' untranslated region of the 
C F T R transcript was used to specifically detect C F T R trans-
gene expression (Engelhardt et al.. 1993). This probe contains 
sequences specific to adenovirus-derived C F T R and hence will 
not hybridize to endogenous baboon C F T R transcripts. Sense 
and antisense ''̂ S R N A probes were generated using the 
Promega riboprobe system. Briefly, sections were fixed in 4 % 
paraformaldehyde followed by dehydration through a graded 
series of ethanol. Sections were treated with 10 p-g/ml protein-
ase K at 30°C for 30 min followed by acetylation in acetic 
anhydride. Following prehybridization for 4 hr at 54°C, sec-
tions were hybridized in I x lO' cpm/ml with sense and an-
tisense probes for 16-18 hr. Sections were exposed to NBT-2 
photoemulsion for I week. 
Southern analysis for adenoviral DNA 
Tissues frozen in liquid nitrogen were used to generate total 
cellular D N A . Samples were digested in T N E containing O.S 
mg/ml proteinase K, 0.1% S D S at 37°C for 16 hr. Samples 
were extracted twice with phenol, once with phenol/chloroform 
(1:1), and twice with chloroform, followed by precipitation in 
isopropanol. D N A was digested with Eco RI, resolved on a 1% 
agarose gel. transfened to nylon, and probed with a random-
primed -'-P-labeled human C F T R c D N A fragment (2,226-
3,714 bp). Controls for the quantitation of adenoviral copy 
number were generated by reconstitution of a known quantity of 






FIG. 3. Cellular distribution of/acZ expression in histochem-
ically stained sections. Frozen (6-p,m| sections from the poste-
rior segment of 4-day animal B4 from the left upper and right 
upper lobes infected with I0'° pfu/ml of Ad.CBCFTR (A) and 
Ad.CMV/acZ (B and C) , and histochemically stained in X-gal 
for 4 hr. br, bronchiole. Bar, 645 p,ni, A and B; 128 p,m, C. 
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RESULTS 
Distribution of transgene expression within the lung 
The distribution of recombinant gene expression within the 
lung following instillation of Ad.CMV/acZ (20 ml of I0'° 
pfu/ml) into an isolated pulmonary segment was evaluated in 
animal B1. Three days after gene transfer, the lung was har-
vested en bloc, inflation fixed, and stained in situ with X-gal. 
Inspection of the lung indicated intense reaction product that 
was primarily confined to the posterior subsegment of the left 
upper lobe, the area into which the virus was instilled (Fig. 1 A, 
see closed anow). A smaller area of blue staining was seen 
within the posterior basal segment of the left lower lobe, prob-
ably due to spillover of virus at the time of bronchoscopy 
(Fig. IA, see open anow). The cellular distribution of lacZ 
expression in this sample analyzed by histologic sections of 
GMA-embedded tissues revealed a predominantly alveolar pat-
tem of staining with infrequent patches of blue staining in 
bronchus and brochioles (data not shown). 
Effect of virus dose on efficiency of gene transfer 
The efficiency and cellular localization of transgene expres-
sion was analyzed in 4 baboons at 4 days and in 4 baboons at 21 
days after infection with Ad.CMV/acZ (left upper lobe) and 
Ad.CBCFTR (right upper lobe) administered at doses of 10' 
pfu/ml (Group D — B 3 , BS), 10** pfu/ml (Group C — B I O , BI4), 
10" pfu/ml (Group B — B l l , B13), and 10'° pfu/ml (Group 
A — B 4 , B6). Tissue blocks harvested from subquadrants of all 
lobes of the lung, except the azygos, were stained en bloc in 
X-gal. Analysis of tissue from animal B 4 harvested 4 days after 
infusion of 10'° pfu/ml of virus revealed high levels of lacZ 
expression in all blocks from the posterior segment of the left 
upper lobe (Fig. 2A) and essentially no expression in blocks 
from all other lobes (data not shown). Examination of this tissue 
under the dissecting microscope localized lacZ expression to 
the alveolar region with patches of blue staining in the larger 
bronchi (Fig. 2B) and bronchioles (data not shown). LacZ ex-
pression was also detected in the posterior segment ofthe upper 
left lobe 4 days after gene transfer in the animal that received 
10" pfu/ml of virus (Bll); the abundance of/acZ-positive cells 
was reduced in comparison to tissues of the animal that received 
the higher dose of virus (compare Fig. 2A to 2C). LacZ expres-
sion was no longer detected in lung tissues of animals 21 days 
postinfection with a similar dose of virus [B6, 10'° pfu/ml 
(Fig. 2E) and B13, 10" pfu/ml (data not shown)]. Transgene 
expression was not detected in tissues harvested 4 and 21 days 
after gene transfer of animals that received 10^ or 10' pfu/ml of 
virus (Fig. 2 D and data not shown, respectively). 
The cellular distribution of lacZ expression was precisely 
defined in X-gal-stained cryosections. As expected, sections 
taken from adjacent subquadrants of tissue that revealed posi-
tive X-gal staining en bloc showed significant levels of lacZ 
expression. Figure 3 presents X-gal histochemical analysis of 
tissues harvested 4 days after administration of 10'° pfu/ml 
vims. Within the posterior segment of left upper lobe, lacZ 
expression was confined predominantly to the alveolar regions 
with lower levels of infrequent patchy staining in bronchioles 
(Fig. 3B,C). N o lacZ staining was observed in segments of the 
right upper lobes that received 10'° pfu/ml of C F T R vims 
(Fig. 3A). Infrequently, small regions of X-gal-stained tissue 
could be seen in areas outside the left upper lobe in the 4-day 
animal receiving 10'° pfu/ml vims. This supports the finding in 
animal BI that recombinant gene expression is essentially local-
ized to the area of the lung into which the vims was instilled. 
Cells in the alveoli that expressed lacZ appeared by morpho-
logic criteria to be both alveolar type I (squamoid morphology) 
and alveolar type II cells (cuboidal morphology). The patchy 
bronchiolar staining appeared to be localized to both nonciliated 
and ciliated cell types. 
Other organs including the heart, liver, spleen, kidney, uri-
nary bladder, brain, and testes were analyzed for lacZ expres-
sion by en bloc histochemical staining of tissues from all 
necropsied animals; in addition, frozen sections from all tissues 
from the animals that received the highest dose of vims were 
analyzed for lacZ expression. The X-gal reaction product was 
absent in all nonpulmonary tissue of all animals with the excep-
tion of the spleen, which consistently demonstrated low levels 
of staining in all animals that was independent of vims dose. 
Similar levels of staining have been demonstrated in spleen 
from untreated mice, rats, and rabbits not treated with lacZ 
vimses, suggesting that this may be due to endogenous P-gal 
activity. 
Table 2. Transgene Expression in Cells Derived from Bronchoalveolar Lavage and Brushings 
B A L ' 
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FIG. 4. Localization of C F T R m R N A by in situ hybridiza-
tion. Serial frozen sections (6 p,m) from the posterior segment 
ofthe right upper lobe from the animal infused with 10'° pfu/ml 
of Ad.CBCFTT? and sacrificed at 4 days were analyzed by 
in situ hybridization to detect the recombinant derived C F T R 
m R N A . Sections were hybridized to a sense (A) and antisense 
(B) ""̂ S-labeled probes encoded in the 3'-untranslated sequence 
ofthe C F T R transgene. Bright field (left) and dark field (right) 
photomicrographs are shown. N o signal above background was 
seen in sections from the posterior segment of the left upper 
lobe (infected with 10'° pfu/ml of Ad.CMV/acZ) hybridized to 
the antisense probes (data not shown) or in any sections har-
vested from all lobes of 21-day animals (data not shown). Bar, 
320 p,m. 
% . 
FIG. 5. Transgene localization in bronchial bmshings. A. 
Histochemical X-gal staining of cytospun bronchial brushings 
from the Ad.CMV/acZ-infused left upper lobe of B4. B. Immu-
nocytochemical C F T R staining of cytospun bronchial brush-
ings from the Ad.CBCFTT? infused right upper lobe of B4. N o 
staining was observed in bmshings taken from B 4 before instil-
lation of virus (data not shown). 
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Recombinant-derived C F T R m R N A in lung tissues 
CFTR transgene expression was analyzed by //( situ hybrid-
ization with a probe specific to the 3'-untranslated region of 
recombinant derived CFTR. Frozen sections from subquadrants 
of each lobe of all animals were hybridized to sense and an-
tisense ̂ "'̂ S-labeled probes and exposed to photoemulsion for 7 
days. Positive signal was seen at highest levels in lung tissue 
harvested 4 days after gene transfer in the animal that received 
10'" pfu/ml of virus (Fig. 4B); the signal was localized to the 
segment of lung into which the Ad.CBCFTR vims was infused 
(i.e.. the posterior segment of the right upper lobe). Animal 
Bll, which received 10'' pfu/ml of virus, demonstrated high-
level expression of recombinant C F T R in a smaller number of 
cells (data not shown). Serial sections hybridized to the sense 
probe gave no signal (Fig. 4A). N o C F T R m R N A was detected 
in animals that received 10" pfu/ml (BIO) and 10' pfu/ml (B3) 
of virus (data not shown). C F T R m R N A expression was unde-
tectable in all lung samples analyzed 21 days after gene trans-
fer. These localization studies substantiate the findings of ana-
tomical confinement, cell distribution, and dose response of 
transgene expression that was demonstrated for Ad.CMV/acZ 
by histochemical analysis. 
Animals were subjected to repeat bronchoscopy 4 and 21 
days after instillation of vims in an attempt to recover cells 
expressing either lacZ or recombinant-derived C F T R (see Si-
mon et al., 1993 for methods). Samples were recovered from 
the right middle lobe before bronchoscopy and the posterior 
segments of the left upper lobe ikicZ .segment) and right upper 
lobe (CFTR segment) 4 and 21 days after gene therapy. Surface 
epithelial cells recovered by bmshing and cells in bronchoalve-
olar lavage fluid were sedimented onto slides. LacZ expression 
was detected by X-gal histochemistry while C F T R expression 
was detected by immunocytochemistry. Results from two ani-
mals (B2 and B8) that received 10'" pfu/ml of virus are summa-
rized in Table 2 and an example of the cytochemical analysis is 
presented in Fig. 5. 
Analysis of bronchoalveolar lavage (BAL) and brushing-
derived cells by X-gal histochemistry revealed easily detectable 
lacZ expression in a significant number of cells at day 4 in the 
animals that receive 10'" pfu/ml of vims. Expression was re-
stricted to cells from the kicZ segment and was no longer 
detected in cells recovered 21 days after gene transfer. Analysis 
of recovered cells lor recombinant C F T R expression by immu-
nocytochemistry revealed virtually identical results: recombi-
nant protein was detected at day 4 and not at day 21 in cells of 
brushings and B A L from the segment into which the highest 
dose of virus was infused. Expression was not detected in cells 
from animals that received lower doses of virus (data not 
shown). The efficiency, distribution and stability of expression 
predicted from these analyses correlates with that demonstrated 
at necropsy. 
Analysis of tissues for adenoviral D N A 
Tissues were evaluated for the presence and abundance of 
adenoviral D N A by Southern blot analysis of Eco Rl-restricted 
total cellular D N A (Fig. 6). Eco Rl releases an internal 1.5-kb 
fragment from the adenoviral genome that hybridizes to human 
C F T R c D N A probe. This probe also detects endogenous ba-
boon C F T R bands that exhibit substantial polymorphism in the 
population of animals that were used in this study. D N A was 
isolated from various sites within the lung of each animal in-
cluding the left upper, left lower, right upper, and right lower 
lobes. A representative autoradiograph is presented in Fig. 6. 
Samples from lungs harvested 4 days after gene transfer demon-
strated viral D N A whose abundance varied with the dose of 
infused virus in the following manner: IO'°pfu/ml, lOcopiesof 
viral D N A per cellular genome (Fig. 6, lane 1); 10" pfu/ml, 2 
copies of viral D N A per cellular genome (Fig. 6, lane 3); 10** 
pfu/ml, O.l copies of viral D N A per cellular genome (Fig. 6, 
laneS);and 10'pfu/ml. <0.05 copies of viral D N A per cellular 
genome (Fig. 6, lane 7). W hen detected, the viral D N A was 
restricted to the lobe into which the C F T R virus was infused. 
Southern analysis of lung samples harvested 21 days after gene 
transfer failed to detect viral D N A with the exception of one 
quadrant of the posterior segment of the right upper lobe of the 
animal infused with 10" pfu/ml vims (BI6) which retained 0.1 
copies of viral D N A per cellular genome (Fig. 6, lane 4). 
Recovery of viral D N A from tissue was greater than 9 5 % as 
estimated by reconstitution experiments in which lung tissue 
homogenates were mixed with a known number of viral parti-
cles before isolation and analysis of D N A (data not shown). 
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FIG. 6. Analysis of recombinant adenoviral D N A . Total cel-
lular D N A (10 p,g) from lungs infected with escalating doses of 
recombinant adenovirus were analyzed at 4 and 21 days. South-
e m blot was hybridized to a •'-P-labeled probe encompassing 
the internal Eco Rl fragment of human CFTR. Lanes I, 3, 5, 
and 7 show D N A samples from the posterior segment of the 
right upper lobe of 4-day animals. Lanes 2, 4, 6, and 8 show 
D N A samples from the posterior segment of the right upper 
lobe of 21-day animals. The various doses of Ad.CBCFTR 
include 10'" pfu/ml, lanes 1 and 2; 10" pfu/ml. lanes 3 and 4; 
IO** pfu/ml, lanes 5 and 6; 10' pfu/ml, lanes 7 and 8. D N A 
samples from the left middle, left lower, right middle, and right 
lower lobes showed no signal (data not shown). Reconstitution 
of genomic D N A with known quantities of human C F T R c D N A 
are shown in lanes 9, 1 copy; lane 10, 10 copies; and lane 11, 
100 copies. The closed arrow marks the I .S-kb diagnostic ade-
noviral D N A fragment. Open anows mark bands that differ in 



























FIG. 7. Localization of adenoviral proteins D B P and fiber within /acZ-expressing cells. Frozen (6-jji,m) sections from posterior segment ofthe left upper lobe (A) of an animal infected 
with 10'" pfu/ml of Ad.CB/acZ were analyzed by triple immunofluorescence for p-gal (detected with AMCA in blue), left; DBP (detected with Texas Red), middle; fiber (detected with 
FITC in green), right. Tissue from the right lower lobe (B) of an animal receiving the lowest dose of virus (10' pfu/ml) that showed no evidence of CFTR or lacZ transsene activity as 
detected by insitu hybridization or histochemical staining in X-gal served as a negative control for antibody specificity (P-gal, left; DBP, middle; fiber, right). Closed anows mark a cell 
that stained positively for p-gal and DPB but had no detectable staining for fiber. Open arrows mark areas of autofluorescence seen in all three channels and also detected in sections not 
treated with secondary antibodies (data not shown). Bar, 53 p,m. 
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Immunocytochemical detection of adenoviral proteins 
D P B and fiber 
Genetically modified lung tissues were evaluated for expres-
sion of adenoviral proteins using techniques of immunocy-
tochemistry in which the product of the lacZ gene was colocal-
ized with protein products of the eariy adenoviral gene E2a 
[DNA binding protein (DBP)] and the fiber protein, which is a 
translation product of the late adenoviral transcriptional unit. 
The specificity and sensitivity of this analysis was previously 
studied in the context of human xenografts infected with wild-
type adenovims and has been described previously (Engelhardt 
et al., 1993). Figure 7A presents the analysis of lung from the 
animal harvested 4 days after infusion of the highest dose of 
vims; on the same field P-gal was detected with A M C A in blue, 
D B P was detected with texas red, and fiber was detected with 
FITC in green. High levels of immunocytochemical staining for 
P-gal was seen within the posterior segment of the left upper 
lobe (Fig. 7A, left), the same area which demonstrated high-
level lacZ expression by X-gal histochemistry. Within the 
group of /acZ-expressing cells were found infrequent cells 
(<0.1% of the total /acZ-expressing population) that expressed 
detectable quantities of D B P (Fig. 7A, middle). D B P always 
colocalized with lacZ. suggesting it was not derived from an 
unrelated virus. Fiber protein was not detected in any cells 
(Fig. 7A, right). Right lower lobes from animals that received 
the lowest dose of vims (10' pfu/ml) served as negative controls 
for antibody specificity and showed no immunoreactive stain-
ing for P-gal, fiber, or D B P (Fig. 7B). 
Recovery of adenovirus from recipient animals 
Each animal was evaluated for recovery of adenovimses by 
infecting 293 cells with the biological sample and evaluating 
the cells for both lacZ expression and the development of cyto-
pathic effects (CPE). Specimens from blood, urine, nasophar-
ynx, stool, and bronchoalveolar lavage fluid were harvested 0, 
4, IS, and 21 days after gene transfer and analyzed for vims. 
The only sample from which vims was recovered was the lav-
age fluid harvested 3 days after gene transfer from the lacZ 
segment of animal B2. All other samples were negative. The 
sensitivity of both the lacZ and C P E assays was consistently 10 
particles of vims per plate. 
D I S C U S S I O N 
Experiments in a variety of small animal models support the 
potential utility of recombinant adenovimses for gene therapy 
of C F lung disease (Rosenfeld et al., 199la,b, 1992; En-
gelhardt et al., 1993). Based, in part, on these studies, we 
proposed a clinical trial for evaluating the biological efficacy 
and safety of recombinant adenovimses for C F gene therapy. 
The general constmct of the proposed clinical experiment is to 
expose a segment of lung to a solution containing CFTR adeno-
vims and to evaluate the recipient for toxicity as well as effi-
ciency and stability ofrecombinant gene expression. The exper-
iments described in this and the following manuscript were 
performed in baboons in an attempt to simulate the proposed 
clinical trial with four treatment groups, each of which received 
a single dose of vims ranging from 10' pfu/ml to I0'° pfu/ml. 
Within each group of the baboon experiments, animals were 
necropsied 4 and 21 days after gene transfer to allow precise 
evaluations of the recipients for gene transfer and toxicity. 
Animals were also followed longitudinally to allow conelation 
between the clinical evaluation of gene therapy with findings at 
necropsy. 
An important aspect of the study design was to expose a 
small and defined area of lung to the virus; the rationale was to 
minimize the portion of lung at risk if toxicity occuned. Analy-
sis of lung tissue indicated that instillation of the vims through a 
bronchoscope resulted in gene transfer moderately well local-
ized to the segment of lung into which the vims was infused. 
These studies also confirmed that recombinant gene expression 
is dose dependent over at least a 3-log concentration of vims. 
Histochemical evaluation of lung tissue revealed a consistent 
pattem ofrecombinant gene expression in which the majority of 
expression was found in alveolar cells with patchy areas of 
expression in bronchi and bronchioles. This is similar to the 
distribution of gene expression we have observed in mice, fer-
rets, and rhesus monkeys (Engelhardt and Wilson, unpublished 
results), however, it contrasts with experiments in cotton rats 
that demonstrated expression primarily in surface epithelial 
cells of the conducting airway (Rosenfeld et al., 1991b; En-
gelhardt, unpublished results). The implications ofthe distribu-
tion of recombinant gene expression found in the baboons to the 
potential of gene therapy of C F is unclear. The regulation of 
CFTR expression in human lung is complex with the existence 
of subpopulations of surface epithelial cells throughout the con-
ducting airway and the alveoli that express high levels of the 
gene (Engelhardt et al., 1992 and in press). In light of this 
complexity, it will be difficult with any strategy of somatic gene 
therapy to reconstitute precisely C F T R expression in the lung. 
Whether the type of genetic reconstitution achieved with re-
combinant adenovimses will be therapeutic will have to await 
efficacy trials in humans or a physiologically relevant animal 
model.. 
An effective gene therapy for C F will require that the.recom-
binant CFTR is expressed for a prolonged period of time and/or 
that the treatment can be administered repeatedly. Experiments 
in baboons indicated that expression of recombinant-derived 
CFTR diminishes significantly within 3 weeks. This apparent 
instability of transgene expression may be explained by several 
mechanisms. In general, diminution of expression may be 
caused by (i) loss of viral D N A because of degradation of the 
episomal viral genome or tumover of the transduced cell, or (ii) 
inactivation of the transcriptional elements responsible for ex-
pression of the transgene. Southern analysis of lung D N A indi-
cated that an important factor leading to loss of transgene ex-
pression was loss of viral D N A . The rate with which diminution 
of transgene expression occuned suggests that it is not likely 
caused by turnover of the cells even if that tumover were accel-
erated in the setting of injury. The most likely explanation is 
that the viral D N A does not integrate and is retained in an 
episomal form that is eventually degraded. This finding is in 
contrast to the results obtained in the human bronchial xe-
nografts where adenovims-expressed C F T R is retained at high 
levels for the life of the grafts (i.e., 2 months, [Engelhardt 
et al.. 1993]). Reasons for these disparate results are not 
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known. However, they may illustrate the limitations of using 
nonhuman animal models to study the biology of human aden-
ovimses. 
In conclusion, we have presented results from a comprehen-
sive preclinical trial in nonhuman primates that address the 
efficiency of recombinant adenoviral vectors as a therapeutic 
vector for gene therapy of CF lung disease. W e are able to 
achieve localized transgene expression in segments of the lung 
which persist for less than 21 days. The mechanism(s) of lack of 
persistence is unknown but suggests that cunent vectors used 
may require multiple administrations to be an effective thera-
peutic tool in the treatment of CF. 
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